Arvinas (ARVN) EBIT (QoQ) (2017 - 2026)
Powered by 
Analysis
Arvinas (ARVN) EBIT (QoQ) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Arvinas | 605.88 Mn | 37.98 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 357.21% |
| Mar 31, 2026 | 14.48% |
| Dec 31, 2025 | -70.32% |
| Sep 30, 2025 | 38.74% |
| Jun 30, 2025 | -200.14% |
| Mar 31, 2025 | 222.68% |
| Dec 31, 2024 | 3.48% |
| Sep 30, 2024 | -24.33% |
| Jun 30, 2024 | 41.78% |
| Mar 31, 2024 | 49.61% |
| Dec 31, 2023 | -123.68% |
| Sep 30, 2023 | 0.94% |
| Jun 30, 2023 | 14.94% |
| Mar 31, 2023 | -16.01% |
| Dec 31, 2022 | -17.57% |
| Sep 30, 2022 | 2.28% |
| Jun 30, 2022 | -14.04% |
| Mar 31, 2022 | -21.47% |
| Dec 31, 2021 | -0.42% |
| Sep 30, 2021 | 8.86% |